Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it will present at the upcoming Nobel Financial Fifth Annual Equity Conference to be held June 8-9, 2009 at Hard Rock Hotel & Casino located in Hollywood, Florida. Antares Pharma’s President and Chief Executive Officer, Paul K. Wottton, Ph.D., will present Monday, June 8th at 12:45 p.m. ET (Eastern Time).

Investors may access the live audio web cast of Antares’ presentation at the following link:http://hosted.mediasite.com/mediasite/Viewer/?peid=efc3ed4062644ca3bddfb0f02307152b. A web cast replay of the presentation may also be accessed via Antares Pharma’s website at www.antarespharma.com under the Investors Relations section until Monday, June 22nd.

About Antares Pharma

Antares Pharma is a product development company committed to improving pharmaceuticals through its patented drug delivery systems. Antares has multiple development partnerships with leading pharmaceutical companies. The Company’s products are designed to improve safety and efficacy profiles by minimizing dosing and reducing side effects while enabling improved patient compliance. The Company’s lead product candidate, Anturol™, an oxybutynin ATD™ gel for the treatment of OAB (overactive bladder), is currently under evaluation in a pivotal Phase III trial. Antares has three validated drug delivery systems: the ATDTM Advanced Transdermal Gel Delivery system, injection technology platforms including both VibexTM disposable pressure assisted auto injectors and Vision® reusable needle-free injectors; and Easy TecTM oral disintegrating tablets (ODT). Two of the systems have generated FDA approved products. Antares Pharma leverages its multiple drug delivery systems to add value to existing drugs and to create new products. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Forward Looking Statements-Safe Harbor

This press release may contain statements which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the intent, belief or current expectations of the Company, its directors, or its officers with respect to the future operating performance of the Company, Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Important factors that could cause such differences are described in the Company's periodic filings with the Securities and Exchange Commission.